This population-based study analyzed 3,482 osteosarcoma cases from the NCI SEER database (1973-2004). It describes incidence and survival across all age groups, races, sexes, anatomic sites, and pathologic subtypes. The goal was to provide the first comprehensive, age-stratified epidemiologic description of this rare tumor.
Most prior osteosarcoma data either focused on pediatric cases or lumped all ages together, obscuring the distinct biology and prognosis of elderly-onset disease. Hospital-based series had also systematically overestimated the proportion of Paget- and radiation-related cases in older patients.
When you see an osteosarcoma in a patient over 60, do not default to assuming it is Paget-related or radiation-induced. This paper shows primary osteosarcoma is the majority presentation even in the elderly, and those patients deserve the same diagnostic and staging workup as younger patients.
When you see a pelvic osteosarcoma at any age, counsel accordingly. Pelvic location predicts the worst outcomes across all age groups — 5-year survival drops to 4.4% in elderly patients with pelvic primaries. This finding should drive early multidisciplinary consultation and surgical planning.
The survival plateau since the mid-1980s is the paper's most important clinical signal. Current chemotherapy regimens have maximized their benefit. Enrollment in clinical trials should be the default recommendation for any osteosarcoma patient, particularly those with distant disease or pelvic primaries.
This population-based study analyzed 3,482 osteosarcoma cases from the NCI SEER database (1973-2004). It describes incidence and survival across all age groups, races, sexes, anatomic sites, and pathologic subtypes. The goal was to provide the first comprehensive, age-stratified epidemiologic description of this rare tumor.
Most prior osteosarcoma data either focused on pediatric cases or lumped all ages together, obscuring the distinct biology and prognosis of elderly-onset disease. Hospital-based series had also systematically overestimated the proportion of Paget- and radiation-related cases in older patients.
When you see an osteosarcoma in a patient over 60, do not default to assuming it is Paget-related or radiation-induced. This paper shows primary osteosarcoma is the majority presentation even in the elderly, and those patients deserve the same diagnostic and staging workup as younger patients.
When you see a pelvic osteosarcoma at any age, counsel accordingly. Pelvic location predicts the worst outcomes across all age groups — 5-year survival drops to 4.4% in elderly patients with pelvic primaries. This finding should drive early multidisciplinary consultation and surgical planning.
The survival plateau since the mid-1980s is the paper's most important clinical signal. Current chemotherapy regimens have maximized their benefit. Enrollment in clinical trials should be the default recommendation for any osteosarcoma patient, particularly those with distant disease or pelvic primaries.